Trademark: 88829946
Word

Status
Dead
Status Code
606
Status Date
Monday, April 18, 2022
Serial Number
88829946
Mark Type
2000
Filing Date
Wednesday, March 11, 2020
Published for Opposition
Tuesday, July 21, 2020
Abandoned Date
Monday, April 18, 2022

Trademark Owner History
Sarepta Therapeutics, Inc. - Owner At Publication

Classifications
5 pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
1 chemical compounds and additives for use in pharmaceutical research; chemical compounds and additives for use in the manufacture of pharmaceuticals; diagnostic reagents for research use
The mark consists of an abstract representation of the DNA double helix structure in white and gold. The color black shown in the mark is background and is not part of the mark.
The color(s) white and gold is/are claimed as a feature of the mark.

Trademark Events
Apr 18, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Apr 18, 2022
Abandonment - No Use Statement Filed
Sep 14, 2021
Notice Of Approval Of Extension Request E-Mailed
Sep 12, 2021
Sou Extension 2 Granted
Sep 12, 2021
Sou Extension 2 Filed
Sep 12, 2021
Teas Extension Received
Mar 10, 2021
Notice Of Approval Of Extension Request E-Mailed
Mar 8, 2021
Sou Extension 1 Granted
Mar 8, 2021
Sou Extension 1 Filed
Mar 8, 2021
Teas Extension Received
Sep 15, 2020
Noa E-Mailed - Sou Required From Applicant
Jul 21, 2020
Official Gazette Publication Confirmation E-Mailed
Jul 21, 2020
Published For Opposition
Jul 1, 2020
Notification Of Notice Of Publication E-Mailed
Jun 16, 2020
Approved For Pub - Principal Register
Jun 13, 2020
Teas/Email Correspondence Entered
Jun 12, 2020
Correspondence Received In Law Office
Jun 12, 2020
Teas Response To Office Action Received
Jun 3, 2020
Notification Of Non-Final Action E-Mailed
Jun 3, 2020
Non-Final Action E-Mailed
Jun 3, 2020
Non-Final Action Written
Jun 3, 2020
Assigned To Examiner
Mar 18, 2020
Notice Of Design Search Code E-Mailed
Mar 17, 2020
New Application Office Supplied Data Entered In Tram
Mar 14, 2020
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24